Massengale William Trent, McBurney Elizabeth, Gurtler Jayne
Department of Dermatology, Louisiana State University Medical School, LA, USA.
J Am Acad Dermatol. 2002 Mar;46(3):441-3. doi: 10.1067/mjd.2002.108490.
Despite cutaneous B-cell lymphoma often having a relatively indolent course and low mortality, it is often resistant to conventional therapy and frequently relapses. We describe a patient with widespread cutaneous B-cell lymphoma who was treated successfully with a recently approved chimeric monoclonal antibody directed against the CD20 antigen (rituximab) and the CD20-negative relapse that resulted.
尽管皮肤B细胞淋巴瘤通常病程相对惰性且死亡率低，但它往往对传统疗法耐药且频繁复发。我们描述了一名患有广泛皮肤B细胞淋巴瘤的患者，该患者用一种最近获批的针对CD20抗原的嵌合单克隆抗体（利妥昔单抗）成功治疗，以及随后出现的CD20阴性复发情况。
